Min Yong Kang
Sungkyunkwan University · Medicine
About the Lab
Professor Min Yong Kang's research lab specializes in regenerative medicine and cancer biology, with a focus on stem cell differentiation for urological tissue engineering and the development of novel therapeutic strategies for genitourinary cancers. The lab investigates the differentiation of human pluripotent stem cells into functional urothelial and kidney cells for cell replacement therapy and disease modeling, while also exploring the anti-cancer effects of statins and autophagy modulation in bladder and prostate cancers. Their work integrates stem cell biology, cancer stem cell-derived organoids, and molecular mechanisms of drug response to advance precision medicine in urological diseases.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Our novel protocol for hPSCs differentiation into NPCs can be useful for producing alternative sources of cell replacement therapy and disease modeling for human kidney diseases.
The use of patient-derived tumor tissues and cells has led to significant advances in personalized cancer therapy and precision medicine. The advent of genomic sequencing technologies has enabled the comprehensive analysis of tumor characteristics. The three-dimensional tumor organoids derived from self-organizing cancer stem cells are valuable ex vivo models that faithfully replicate the structure, unique features, and genetic characteristics of tumors. These tumor organoids have emerged as inn
// Minyong Kang 1 , Chang Wook Jeong 1 , Cheol Kwak 1 , Hyeon Hoe Kim 1 , Ja Hyeon Ku 1 1 Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea Correspondence to: Ja Hyeon Ku, email: kuuro70@snu.ac.kr Keywords: urothelial carcinoma, urinary bladder, systemic inflammatory response, neutrophil-lymphocyte ratio, predictors Received: July 25, 2016     Accepted: November 24, 2016     Published: December 26, 2016 ABSTRACT The progno
Statins are cholesterol reduction agents that exhibit anti-cancer activity in several human cancers. Because autophagy is a crucial survival mechanism for cancer cells under stress conditions, cooperative inhibition of autophagy acts synergistically with other anti-cancer drugs. Thus, this study investigates whether combined treatment of atorvastatin and autophagy inhibitors results in enhancing the cytotoxic effects of atorvastatin, upon human bladder cancer cells, T24 and J82, in vitro. To mea
Human stem cells are promising sources for bladder regeneration. Among several possible sources, pluripotent stem cells are the most fascinating because they can differentiate into any cell type, and proliferate limitlessly in vitro. Here, we developed a protocol for differentiation of human pluripotent stem cells (hPSCs) into bladder urothelial cells (BUCs) under a chemically defined culture system. We first differentiated hPSCs into definitive endoderm (DE), and further specified DE cells into
We examined the anti-cancer effects and molecular mechanism of simvastatin in human castration-resistant prostate cancer (CRPC) cells, particularly focused on LIN28B and its target molecule, let-7 microRNA (miRNA) among the various target genes of NF-κB. A human CRPC cell line (PC3) was used in the current study. Gene expression patterns were evaluated using real time-PCR and western blot analysis. CCK-8 assay was used for assessing cell viability and proliferation, and a clonogenic assay was ad
// Minyong Kang 1 , Chang Wook Jeong 1 , Cheol Kwak 1 , Hyeon Hoe Kim 1 , Ja Hyeon Ku 1 1 Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea Correspondence to: Ja Hyeon Ku, email: kuuro70@snu.ac.kr Keywords: urinary bladder neoplasm, chemotherapy, drug therapy, single instillation, systematic review Received: March 18, 2016 Accepted: May 29, 2016 Published: June 14, 2016 ABSTRACT We performed a network m
We evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes, we collected 10 ml of blood from 20 patients at the time of radical nephrectomy. We analyzed somatic mutations in primary tumors and ctDNA samples from these patients. We finally collected 10 ml of blood befo
Despite the potential therapeutic efficacy of epithelial growth factor receptor (EGFR) inhibitors in the treatment of advanced stage bladder cancer, there currently is no clear evidence to support this hypothesis. In this study, we investigate whether the concurrent treatment of autophagy-blocking agents with EGFR inhibitors exerts synergistic anti-cancer effects in T24 and J82 human bladder cancer cells. Lapatinib and gefitinib were used as EGFR inhibitors, and bafilomycin A1 (BFA1), chloroquin
In summary, our data highlighted that tumor size and nephrometry score, which are tumor-related factors, as well as the surgeon's experience, a surgeon-related factor, appear to be the critical predictive factors for Pentafecta achievement following RAPN.
Research Areas
Dive deeper into Min Yong Kang's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.